Navigation Links
Watching, Reading and Listening: A New Way to Interact with Patient Information

TITUSVILLE, N.J., April 24, 2012 /PRNewswire/ -- It lies within the compact folded rectangle that accompanies prescription medicines. In black and white on paper, it follows prescription medicine advertisements in magazines and newspapers. Known as patient information, it is frequently part of the U.S. Food and Drug Administration (FDA) approved labeling for prescription medicines.

To view the multimedia assets associated with this release, please click:

For many, it can be an important everyday resource to learn what they need to know about the medication they are taking--what it does, how to take it, possible drug interactions, serious side effects and symptoms that might be signs of a side effect.

To enhance patients' access to and use of this information, Janssen Therapeutics, Division of Janssen Products, LP has launched a pilot program--and a first for the Johnson & Johnson family of companies--designed to transform the experience of exploring this information online through digital storytelling and animation.

This new tool, for the prescription medicine PREZISTA® (darunavir), is called The PREZISTA Zone and can be found at It enables users to read, listen to and interact with information about the product. Features include:

  • A selection of eight animated hosts who serve as site guides and narrate the Patient Information.
  • The story of Jacob, a man who has just been diagnosed with a chronic disease, told through a series of seven animated clips that help illustrate sections of the Patient Information.
  • In the first episode, Jacob attends a disease support group session and learns how PREZISTA works.
  • In subsequent clips, he visits his physician to learn about medicines that should not be taken with PREZISTA, and visits his pharmacist who reviews the possible side effects of PREZISTA.
  • "As a physician, I know from experience that people tend to learn in different ways, and that can pose different kinds of challenges for patients trying to educate themselves about their medications," said Bryan Baugh, MD, Medical Director at Janssen Therapeutics.  "We designed The PREZISTA Zone to meet a variety of personal preferences for learning and interacting with online information. We're very excited to introduce this pilot program; it hasn't been done before for products like PREZISTA."

    In a recent omnibus survey of 1,047 people, which was sponsored by Janssen Therapeutics, 60 percent of those surveyed agreed it would be helpful to review Patient Information in an animated version that can be viewed and listened to online.[1]

    "When you have a chronic illness, starting treatment for the first time or switching your medication can sometimes be overwhelming," said Jeff Berry,* Director of Publications, Test Positive Aware Network (TPAN) in Chicago. "This interactive version of Patient Information is an innovative approach to helping people learn about their medicines based on information from the FDA-approved patient labeling.  I hope this initiative will encourage the development of other educational tools that go beyond the printed page."

    *Jeff Berry is a paid consultant for Janssen Therapeutics.

    About PREZISTA®PREZISTA® (darunavir) is a prescription medicine. It is one treatment option in the class of HIV (human immunodeficiency virus) medicines known as protease inhibitors.

    PREZISTA® is always taken with and at the same time as ritonavir (Norvir®), in combination with other HIV medicines for the treatment of HIV infection in adults. PREZISTA® should also be taken with food.

  • The use of other medicines active against HIV in combination with PREZISTA®/ritonavir (Norvir®) may increase your ability to fight HIV. Your healthcare professional will work with you to find the right combination of HIV medicines
  • It is important that you remain under the care of your healthcare professional during treatment with PREZISTA®
  • PREZISTA® does not cure HIV infection or AIDS and you may continue to experience illnesses associated with HIV-1 infection, including opportunistic infections. You should remain under the care of a doctor when using PREZISTA®.Please read Important Safety Information below, and talk to your healthcare professional to learn if PREZISTA® is right for you.Important Safety InformationWhat is the most important information I should know about PREZISTA?

  • PREZISTA® can interact with other medicines and cause serious side effects. See "Who should not take PREZISTA®?"
  • PREZISTA® may cause liver problems. Some people taking PREZISTA®, together with Norvir® (ritonavir), have developed liver problems which may be life-threatening. Your healthcare professional should do blood tests before and during your combination treatment with PREZISTA®. If you have chronic hepatitis B or C infection, your healthcare professional should check your blood tests more often because you have an increased chance of developing liver problems
  • Tell your healthcare professional if you have any of these signs and symptoms of liver problems: dark (tea-colored) urine, yellowing of your skin or whites of your eyes, pale-colored stools (bowel movements), nausea, vomiting, pain or tenderness on your right side below your ribs, or loss of appetite
  • PREZISTA® may cause a severe or life-threatening skin reaction or rash. Sometimes these skin reactions and skin rashes can become severe and require treatment in a hospital. You should call your healthcare professional immediately if you develop a rash. However, stop taking PREZISTA® and ritonavir combination treatment and call your healthcare professional immediately if you develop any skin changes with these symptoms: fever, tiredness, muscle or joint pain, blisters or skin lesions, mouth sores or ulcers, red or inflamed eyes, like "pink eye." Rash occurred more often in patients taking PREZISTA® and raltegravir together than with either drug separately, but was generally mild
  • Who should not take PREZISTA®?

  • Do not take PREZISTA® if you are taking the following medicines: alfuzosin (Uroxatral®), dihydroergotamine (D.H.E.45®, Embolex®, Migranal®), ergonovine, ergotamine (Cafergot®, Ergomar®), methylergonovine, cisapride (Propulsid®), pimozide (Orap®), oral midazolam, triazolam (Halcion®), the herbal supplement St. John's wort (Hypericum perforatum), lovastatin (Mevacor®, Altoprev®, Advicor®), simvastatin (Zocor®, Simcor®, Vytorin®), rifampin (Rifadin®, Rifater®, Rifamate®, Rimactane®), sildenafil (Revatio®) when used to treat pulmonary arterial hypertension, indinavir (Crixivan®), lopinavir/ritonavir (Kaletra®), saquinavir (Invirase®), or telaprevir (Incivek™)
  • Before taking PREZISTA®, tell your healthcare professional if you are taking sildenafil (Viagra®, Revatio®), vardenafil (Levitra®, Staxyn®), tadalafil (Cialis®, Adcirca®), atorvastatin (Lipitor®), rosuvastatin (Crestor®), pravastatin (Pravachol®), or colchicine (Colcrys®, Col-Probenecid®). Tell your healthcare professional if you are taking estrogen-based contraceptives (birth control). PREZISTA® might reduce the effectiveness of estrogen-based contraceptives. You must take additional precautions for birth control, such as condoms
  • This is not a complete list of medicines. Be sure to tell your healthcare professional about all the medicines you are taking or plan to take, including prescription and nonprescription medicines, vitamins, and herbal supplements.What should I tell my doctor before I take PREZISTA®?

  • Before taking PREZISTA®, tell your healthcare professional if you have any medical conditions, including liver problems (including hepatitis B or C), allergy to sulfa medicines, diabetes, or hemophilia
  • Tell your healthcare professional if you are pregnant or planning to become pregnant, or are breastfeeding
  • The effects of PREZISTA® on pregnant women or their unborn babies are not known. You and your healthcare professional will need to decide if taking PREZISTA® is right for you
  • Do not breastfeed. It is not known if PREZISTA® can be passed to your baby in your breast milk and whether it could harm your baby. Also, mothers with HIV should not breastfeed because HIV can be passed to your baby in the breast milk
  • What are the possible side effects of PREZISTA®?

  • High blood sugar, diabetes or worsening of diabetes, and increased bleeding in people with hemophilia have been reported in patients taking protease inhibitor medicines, including PREZISTA®
  • Changes in body fat have been seen in some patients taking HIV medicines, including PREZISTA®. The cause and long-term health effects of these conditions are not known at this time
  • Changes in your immune system can happen when you start taking HIV medicines. Your immune system may get stronger and begin to fight infections that have been hidden
  • The most common side effects related to taking PREZISTA® include diarrhea, nausea, rash, headache, stomach pain, and vomiting. This is not a complete list of all possible side effects. If you experience these or other side effects, talk to your healthcare professional. Do not stop taking PREZISTA® or any other medicines without first talking to your healthcare professional
  • You are encouraged to report negative side effects of prescription drugs to the FDA. Visit, or call 1-800-FDA-1088.Please refer to the ritonavir (Norvir®) Product Information (PI and PPI) for additional information on precautionary measures.

    Please see full Prescribing Information for more details, available at

    About Janssen Therapeutics At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in HIV and other infectious diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Headquartered in Titusville, New Jersey, Janssen Therapeutics, Division of Janssen Products, LP, is one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Visit for more information. Follow us on Twitter at @JanssenUS.

    Reference: 1. About The Survey: This Janssen Therapeutics study was conducted by StrategyOne using Toluna field services, among 1,047 US residents.  The survey was fielded April 9th – 11th, 2012 and the data were weighted to be representative to US Census. These data have a margin of error +- 3.03% at the 95% confidence interval. Media Contact:

    Tricia GeogheganOffice: (609) 730-3746Mobile: (609) 462-8764Email:


    SOURCE Janssen Therapeutics
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Transitions Optical and VSP Vision Care Partner with Bess the Book Bus to Bring Healthy Vision and a Love of Reading to Palmetto Elementary Students
    2. Bringing Pain Management to Africa: Spreading Relief Through Training
    3. TeleHealth Services and Reading Hospital and Medical Center Partner to Reach Technology-Driven Patient Education Goals
    4. Face Masks Offer Protection Against Spreading H1N1
    5. The CementBloc and Novartis Vaccines to Jointly Present Top Considerations in Interactive Selling at the 11th Annual iPharmaConnect
    6. Medco Study Finds Many Patients on Newer Oncology Treatments Are at Risk for Drug Interactions
    7. LodgeNet Interactive to Report Fourth Quarter and Full Year 2011 Results on February 22nd
    8. Study Finds No Drug-Drug Interaction Between Aggrenox® (aspirin/extended-release dipyridamole) 25mg/200mg Capsules and Omeprazole, a Widely Used PPI
    9. Centra Health and TeleHealth Services Partner to Launch Enterprise Interactive Patient Education for Patient Satisfaction and Safety
    10. Homestead of Sherman Uses AccuNurse Interactive Care to Improve Care and Service
    11. Ira Haimowitz, PhD, EVP, at The CementBloc, to Present on Best Practices in iPad Interactive Selling at 11th Annual ePharma Summit™
    Post Your Comments:
    (Date:11/30/2015)... Nuance Communications, Inc. (NASDAQ: NUAN ) and ... today jointly announced a new integrated set of clinical ... College of Radiology,s (ACR) Imaging 3.0™ tools to enable ... current and emerging value-based payment models . ... clinical decision support, radiology reporting and image sharing technology ...
    (Date:11/30/2015)... , Nov. 30, 2015  Novartis will demonstrate ... the 57 th American Society of Hematology (ASH) ... and myelomas as well as supportive care, including key ... to personalized cell therapies. The ASH Annual Meeting will ... . Novartis Oncology . "We will ...
    (Date:11/30/2015)... IRVINE, Calif. and REHOVOT, Israel ... privately held specialty pharmaceutical company focused on acquiring and ... disorders, today announced the appointment of Keith A. ... directors. Gregory J. Flesher , chief executive ... experience in building successful organizations.  As chairman, he will ...
    Breaking Medicine Technology:
    (Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen ... plastic surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, ... giant Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global ...
    (Date:11/30/2015)... EMIGSVILLE, PA (PRWEB) , ... November 30, 2015 ... ... (CCMS) software provider, has verified that their Vasont Universal Integrator (VUI) extension unites ... handle creating, editing, and managing content as a continuous process with the latest ...
    (Date:11/30/2015)... Maryland (PRWEB) , ... November 30, 2015 , ... ... interactions could be of critical importance to the medical schools of the future. ... exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized by ...
    (Date:11/30/2015)... ... 30, 2015 , ... Innovaacom, a leading provider of medical ... survey of educational needs for pharmacists worldwide. The poll of pharmacists in Europe, ... quality online and face-to-face education for pharmacists who are fast becoming the new ...
    (Date:11/30/2015)... ... November 30, 2015 , ... ... In 2016, expected coding changes are likely to include new codes for spine ... not easy to understand the effects of code changes in musculoskeletal, radiology and ...
    Breaking Medicine News(10 mins):